Abstract
We present here a case of severe congestive cardiac failure, in a 47-year-old patient with myeloma who had no prior cardiac history, after receiving bortezomib. Bortezomib is a boron-containing molecule, which reversibly inhibits the proteasome, an intracellular organelle, which is central to the breakdown of ubiquitinated proteins and consequently crucial for normal cellular homeostasis. Phase II clinical trials demonstrate that it is effective for the treatment of relapsed refractory myeloma. Acute development of congestive cardiac failure associated with bortezomib therapy occurs very rarely or may be underestimated. Inhibition of proteasome activity may impair cardiac function due to accumulation of unfolded, damaged and undegraded proteins in myocytes. Patients with or without cardiac disease or previously received anthracycline-containing regimes should be closely monitored when being subjected to treatment with bortezomib.
Similar content being viewed by others
References
Zolk O, Schenke C, Sarikas A. The ubiquitin–proteasome system: focus on the heart. Cardiovasc Res. 2006;70:410–21. doi:10.1016/j.cardiores.2005.12.021.
Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003;426:895–6. doi:10.1038/nature02263.
Hermann J, Ciechanover A, Lerman LO, Lerman A. The ubiquitin–proteasome system in cardiovascular disease: a hypothesis extended. Cardiovasc Res. 2004;1:11–21. doi:10.1016/j.cardiores.2003.09.033.
Vink J, Cloos J, Kaspers GJL. Proteasome inhibition as novel treatment strategy in leukemia. Br J Haematol. 2006;134:253–62. doi:10-1111/j.1315-2141.2006.06170.x.
Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615–22.
Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002;16:433–43. doi:10.1038/sj.leu.2402417.
Yu J, Tiwari S, Steiner P, Zhang L. Differentian apoptotic response to the proteasome inhibitor bortezomib [Velcade, PS-341] in Bax-deficient and p21 deficient colon cancer cells. Cancer Biol Ther. 2003;2:694–9.
Fujioka S, Schmidt C, Sclabas GM, et al. Stabilization of p53 in a novel mechanism for proapoptotic function of NF-kappa B. J Biol Chem. 2004;279:27549–59. doi:10.1074/jbc.M313435200.
Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist. 2007;12:664–89. doi:10.1634/theoncologist.12-6-64.
Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 2006;6:129. doi:10.1186/1471-2407-6-129.
Suvannasankha A, Smith GG, Juliar BE, Abonour R. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma. 2006;7:101–2.
Suvannasankha A, Fausel C, Juliar BE, et al. Final report of toxicity and efficacy of a Phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. Oncologist. 2007;12:99–106. doi:10.1634/theoncologist.12-1-99.
Orcivolo E, Buda G, Cecconi N, et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol. 2007;138:396–403. doi:10.1111/j.1365-2141.2007.06659.x.
Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS_341): a novel, first class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003;10:361–9.
Powell SR. The ubiquitin–proteasome system in cardaic physiology and pathology. Am J Physiol Heart Circ Physiol. 2006;291:H1–19. doi:10.1152/ajpheart.00062.2006.
Willis MS, Patterson C. Into the heart: the emerging role of the ubiquitin–proteasome system. J Mol Cell Cardiol. 2006;41:567–79. doi:10.1016/j.yjmcc.2006.07.015.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hacihanefioglu, A., Tarkun, P. & Gonullu, E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 88, 219–222 (2008). https://doi.org/10.1007/s12185-008-0139-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-008-0139-7